Douglas Mullen, PhD

Doug co-leads the Health Advances’ rare disease practice and has extensive experience in new product planning, portfolio and LCM strategy, commercialization strategy, and M&A. He also co-leads the firm’s investor support practice, where he supports investors with commercial due diligence and deal advisory specifically with transactions in biopharma therapeutics.

He joined Health Advances in 2017 after working in growth strategy consulting at Fletcher Spaght, Inc. and new venture creation at the University of Michigan.

He holds a BSE in mechanical engineering from Duke University, and a PhD & MSE in macromolecular science and engineering from the University of Michigan where his research focused on polymeric nanoparticle-based drug delivery for oncology, autoimmune, and non-viral gene therapy applications.